Twilio Segment Releases 2022 CDP Report, Finds CDPs Booming as Businesses Look Beyond Cookies
Annual report reveals another record-breaking year of API calls on the Twilio Segment platform, signals…
Month: February 2022
Hammerspace Expands European Presence with New London-based Office, Sales Leadership and Channel Expansion
Rapid European Customer Growth in Enterprise, Genomic Research, Online Gaming, and Media and Entertainment Drive…
SoundHound to Participate in 2nd Annual Cowen Mobility Disruption Conference on March 4, 2022
SANTA CLARA, Calif.–(BUSINESS WIRE)–SoundHound Inc., a global leader in voice artificial intelligence (AI), currently in…
Bluewave Expands Executive Expertise with New Leadership Appointments
Seasoned telecom experts join Bluewave’s growing roster of industry leaders PARSIPPANY, N.J.–(BUSINESS WIRE)–#CTO—Bluewave Technology Group…
Kumu Networks Announces Full Duplex Chip to Meet Future 5G Advanced Needs
Kumu Demonstrates “Camelot” RFIC capable of providing the self-interference cancellation required for sub-band full duplex…
6 GHz unlicensed access and Wi-Fi 6E to add billions to Indonesian and African economies, reveals Dynamic Spectrum Alliance
It is predicted that unlicensed access to the 6 GHz band will add US$ 187.63…
Codasip’s latest RISC-V embedded cores enable AI/ML edge customization
Munich, 24 February 2022 – Codasip, the leader in processor design automation, today announced the…
Infovista launches Ativa™ for Cloud-Native Automated Assurance and Operations
Ativa suite provides 360° intelligence and operations across digital experiences, apps, services, networks and infrastructure…
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on…
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical…
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel…
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults…
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor,…
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM,…
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader…
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96…
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with…